Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 10 , Pages 770-775 , October 2011

Plasma adiponectin is associated with less atherogenic lipoprotein phenotype

  • M.-J. Shin

      Affiliations

    • Department of Food and Nutrition, Korea University, Seoul 136-703, Republic of Korea
    • Corresponding Author InformationCorresponding author. Department of Food and Nutrition, Korea University, Seoul 136-703, Republic of Korea. Tel.: +82 2 940 2857; fax: +82 2 940 2850.
    • ,
  • O.Y. Kim

      Affiliations

    • Yonsei University Research Institute of Science for Aging, Yonsei University, Seoul 120-749, Republic of Korea

Received 25 August 2009 ,Revised 19 January 2010 ,Accepted 19 January 2010.

References 

  1. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96:939–949
  2. Berg AH, Lin Y, Lisanti MP, Scherer PE. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am J Physiol Endocrinol Metab. 2004;287:E1178–E1188
  3. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935
  4. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–1599
  5. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318–1323
  6. Li S, Shin JH, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes. JAMA. 2009;302:179–188
  7. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;54:534–539
  8. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–89
  9. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–1737
  10. Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 2005;25:e15–e16
  11. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1–4
  12. Williams PT, Krauss RM, Vranizan KM, Stefanick ML, Wood PD, Lindgren FT. Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women. Arterioscler Thromb Vasc Biol. 1992;12:332–340
  13. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb Vasc Biol. 1991;11:174–182
  14. Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?. J Atheroscler Thromb. 2005;12:237–239
  15. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005;5:379–387
  16. Simon J, Lin F, Hulley S, Blanche P, Waters D, Shiboski S, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the cholesterol and pharmacogenetics (CAP) study. Am J Cardiol. 2006;97:843–850
  17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  18. Dreon DM, Fernstrom HA, Williams PT, Krauss RM. Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns. Am J Clin Nutr. 2000;71:1611–1616
  19. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981;665:408–419
  20. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  21. Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167–175
  22. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care. 2003;26:3226–3229
  23. Isobe T, Saitoh S, Tagagi S, Takeuchi H, Chiba Y, Katoh N, et al. Influence of gender, age and renal function on plasma adiponectin concentration: the Tanno and Sobetsu study. Eur J Endocrinol. 2005;135:91–98
  24. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2006;281:2654–2660
  25. Hopkins TA, Ouchi N, Shibata R, Walsh Kenneth. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74:11–18
  26. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S, et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem. 2005;51:578–585
  27. von Eynatten M, Schneider JG, Humpert MG, Rudofsky G, Schmidt N, Barosch P, et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care. 2004;27:2925–2929
  28. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?. Diabetes. 2005;54:795–802
  29. Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes. 2008;57:1824–1833
  30. Brudasca I, Cucuianu M. Pathogenic role of abnormal fatty acids and adipokines in the poral flow. Relevance for metabolic syndrome, hepatic steatosis and steatohepatitis. Rom J Intern Med. 2007;45:149–157
  31. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res. 2005;46:1369–1379
  32. Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol. 2006;290:G194–G198
  33. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, et al. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism. 1992;41:1193–1198
  34. Van der Mooren MJ, deGraaf J, Demacker PNM, de Haan PNM, Rolland R. Changes in the low-density lipoprotein profile during 17b-estradiol-dydrogesterone therapy in postmenopausal women. Metabolism. 1994;43:799–803
  35. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res. 1994;35:2083–2093
  36. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46:459–469
  37. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes. 2008;32:772–779
  38. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36:421–429
  39. Vergès B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, et al. Adiponectin is an important determinant of ApoA-I catabolism. Arterioscler Thromb Vasc Biol. 2006;26:1364–1369
  40. Matsuura F, Oku H, Kosekia M, Sandovala JC, Yuasa-Kawasea M, Tsubakio-Yamamotoa K, et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun. 2007;358:1091–1095
  41. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després J-P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 1997;17:1098–1105
  42. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunjell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb Vasc Biol. 1993;14:147–153
  43. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27:1496–1504

PII: S0939-4753(10)00034-7

doi: 10.1016/j.numecd.2010.01.014

Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 10 , Pages 770-775 , October 2011

Article Tools